Cargando…
Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial
BACKGROUND: Ramucirumab plus docetaxel combination therapy (DOC/RAM) for advanced non-small cell lung cancer (NSCLC) achieves favorable outcomes; however, efficacy and safety for patients with brain metastases are still unclear. METHODS: Eligible patients included those with advanced NSCLC with meas...
Autores principales: | Tanimura, Keiko, Uchino, Junji, Kimura, Hideharu, Hiranuma, Osamu, Chihara, Yusuke, Tanzawa, Shigeru, Takumi, Chieko, Kita, Toshiyuki, Inoue, Koji, Minato, Koichi, Takemoto, Shinnosuke, Nakao, Akira, Yoshimura, Kenichi, Takayama, Koichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243767/ https://www.ncbi.nlm.nih.gov/pubmed/37053467 http://dx.doi.org/10.1093/oncolo/oyad013 |
Ejemplares similares
-
A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study
por: Chihara, Yusuke, et al.
Publicado: (2022) -
Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M‐Positive Non‐Small‐Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial
por: Nakao, Akira, et al.
Publicado: (2019) -
A Phase II Study of S‐1 and Paclitaxel Combination Therapy as a First‐Line Treatment in Elderly Patients with Advanced Non‐Small Cell Lung Cancer
por: Yoshimura, Akihiro, et al.
Publicado: (2018) -
Treatment rationale and design of the RAMNITA study: A phase II study of the efficacy of docetaxel + ramucirumab for non–small cell lung cancer with brain metastasis
por: Tanimura, Keiko, et al.
Publicado: (2018) -
Phase II Study of S‐1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non‐Small Cell Lung Cancer
por: Chihara, Yusuke, et al.
Publicado: (2019)